EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response

Ilina Dimitrova Micheva, Svilena Angelova Atanasova

Frontiers in Oncology · 02.08.2024 · 14

DOI: 10.3389/fonc.2024.1410656 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 02.08.2024. Verfasst von Ilina Dimitrova Micheva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, University Hospital St. Marina, Varna, Bulgaria. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelodysplastic syndromes (MDS) are a group of malignant clonal hematological disorders with heterogeneous clinical course and risk of transformation to acute myeloid leukemia. Genetic and epigenetic dysregulation, including alterations in microRNA (miRNA) expression, plays a pivotal role in MDS pathogenesis influencing disease development and progression. MiRNAs, known for their regulatory roles in gene expression, have emerged as promising biomarkers in various malignant diseases. This review aims to explore the diagnostic and prognostic roles of miRNAs in MDS. We discuss research efforts aimed at understanding the clinical utility of miRNAs in MDS management. MiRNA dysregulation is linked to specific chromosomal abnormalities in MDS, providing insights into the molecular landscape of the disease. Circulating miRNAs in plasma offer a less invasive avenue for diagnostic and prognostic assessment, with distinct miRNA profiles identified in MDS patients. Additionally, we discuss investigations concerning the role of miRNAs as markers for treatment response to hypomethylating and immunomodulating agents, which could lead to improved treatment decision-making and monitoring. Despite significant progress, further research in larger patient cohorts is needed to fully elucidate the role of miRNAs in MDS pathogenesis and refine personalized approaches to patient care.

Schlagwörter

Stichwörter der Autor:innen

circulating microRNAdiagnostic and prognostic biomarkersmicroRNAmyelodysplastic syndromestherapeutic microRNAs

Autor:innen und Institutionen

  • Hematology Department, University Hospital St. Marina, Varna, Bulgaria.
  • Faculty of Medicine, Medical University of Varna, Varna, Bulgaria.

Zitieren

APA

Micheva, I. D., & Atanasova, S. A. (2024). MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1410656

Vancouver

Micheva ID, Atanasova SA. MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1410656

BibTeX
@article{Micheva2024,
  author = {Micheva, Ilina Dimitrova and Atanasova, Svilena Angelova},
  title = {MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1410656}
}
Kostenlos starten →